SCHAUMBURG, Ill.--(BUSINESS WIRE)--Jan 17, 2008 - APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today announced that it has launched Granisetron Hydrochloride Injection, 0.1 mg/mL, 1 mL single dose vials, the generic equivalent of Hoffmann-LaRoche's Kytril(R) Injection. APP's Granisetron is AP-rated, preservative and latex-free, and bar-coded. According to IMS data, branded sales of this dosage form of Granisetron are expected to be approximately $3.3 million in 2007.
Granisetron Hydrochloride Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high dose cisplatin and radiation cancer therapy. Granisetron Hydrochloride Injection is also indicated for the prevention of postoperative nausea and/or vomiting.
No comments:
Post a Comment